中华内分泌外科杂志
中華內分泌外科雜誌
중화내분비외과잡지
CHINESE JOURNAL OF ENDOCRINE SURGERY
2013年
1期
34-37,41
,共5页
吕云福%何超%谢贤和%顾文彪
呂雲福%何超%謝賢和%顧文彪
려운복%하초%사현화%고문표
Galectin-3%Cyclin D1%免疫组化%甲状腺癌
Galectin-3%Cyclin D1%免疫組化%甲狀腺癌
Galectin-3%Cyclin D1%면역조화%갑상선암
Galectin-3%Cyclin D1%Immunohistochemistry%Thyroid cancer
目的 探讨Galectin-3和Cyclin D1在良、恶性甲状腺肿块中的表达及鉴别价值.方法 用免疫组化(SP)法检测31例结节性甲状腺肿(A组)、65例甲状腺乳头癌(B组)及10例正常甲状腺组织(C组)石蜡标本中Galectin-3蛋白和Cyclin D1蛋白的表达,并结合临床资料分析.结果 B组中Galectin-3的阳性率为83.03%(54/65),显著高于A组的19.35%(6/31)和C组(0%),前2组比较差异有统计学意义(x2 =36.360,P<0.05);B组中Cyclin D1的阳性率为72.30%(47/65),显著高于A组12.90%(4/31)和C组(0%),前2组比较差异有统计学意义(x2=29.740,P<0.05);联合检测Galectin-3和Cyclin D1在良、恶性甲状腺肿瘤中的表达,发现阳性表达差异有统计学意义(P<0.01),且Galectin-3和Cyclin D1在B组中的表达也存在正相关(R=0.509,P<0.05).Cyclin D1蛋白在有无淋巴结转移的甲状腺乳头癌中的阳性率分别为90%(18/20)和64.44% (29/45),差异有统计学意义(P<0.05).结论 Galectin-3和Cyclin D1在甲状腺乳头癌组织中的阳性表达存在正相关性,较结节性甲状腺肿和正常组织有强阳性表达,联合检测甲状腺组织中β-catenin及Galcetin-3的表达有助于甲状腺癌的诊断.
目的 探討Galectin-3和Cyclin D1在良、噁性甲狀腺腫塊中的錶達及鑒彆價值.方法 用免疫組化(SP)法檢測31例結節性甲狀腺腫(A組)、65例甲狀腺乳頭癌(B組)及10例正常甲狀腺組織(C組)石蠟標本中Galectin-3蛋白和Cyclin D1蛋白的錶達,併結閤臨床資料分析.結果 B組中Galectin-3的暘性率為83.03%(54/65),顯著高于A組的19.35%(6/31)和C組(0%),前2組比較差異有統計學意義(x2 =36.360,P<0.05);B組中Cyclin D1的暘性率為72.30%(47/65),顯著高于A組12.90%(4/31)和C組(0%),前2組比較差異有統計學意義(x2=29.740,P<0.05);聯閤檢測Galectin-3和Cyclin D1在良、噁性甲狀腺腫瘤中的錶達,髮現暘性錶達差異有統計學意義(P<0.01),且Galectin-3和Cyclin D1在B組中的錶達也存在正相關(R=0.509,P<0.05).Cyclin D1蛋白在有無淋巴結轉移的甲狀腺乳頭癌中的暘性率分彆為90%(18/20)和64.44% (29/45),差異有統計學意義(P<0.05).結論 Galectin-3和Cyclin D1在甲狀腺乳頭癌組織中的暘性錶達存在正相關性,較結節性甲狀腺腫和正常組織有彊暘性錶達,聯閤檢測甲狀腺組織中β-catenin及Galcetin-3的錶達有助于甲狀腺癌的診斷.
목적 탐토Galectin-3화Cyclin D1재량、악성갑상선종괴중적표체급감별개치.방법 용면역조화(SP)법검측31례결절성갑상선종(A조)、65례갑상선유두암(B조)급10례정상갑상선조직(C조)석사표본중Galectin-3단백화Cyclin D1단백적표체,병결합림상자료분석.결과 B조중Galectin-3적양성솔위83.03%(54/65),현저고우A조적19.35%(6/31)화C조(0%),전2조비교차이유통계학의의(x2 =36.360,P<0.05);B조중Cyclin D1적양성솔위72.30%(47/65),현저고우A조12.90%(4/31)화C조(0%),전2조비교차이유통계학의의(x2=29.740,P<0.05);연합검측Galectin-3화Cyclin D1재량、악성갑상선종류중적표체,발현양성표체차이유통계학의의(P<0.01),차Galectin-3화Cyclin D1재B조중적표체야존재정상관(R=0.509,P<0.05).Cyclin D1단백재유무림파결전이적갑상선유두암중적양성솔분별위90%(18/20)화64.44% (29/45),차이유통계학의의(P<0.05).결론 Galectin-3화Cyclin D1재갑상선유두암조직중적양성표체존재정상관성,교결절성갑상선종화정상조직유강양성표체,연합검측갑상선조직중β-catenin급Galcetin-3적표체유조우갑상선암적진단.
Objectives To investigate the expression and differential diagnosis value of Galectin-3 and Cyclin D1 in benign and malignant thyroid mass.Methods The expression of Galectin-3 and Cyclin D1 protein in 31 cases of nodular goiter(group A),65 cases of papillary thyroid carcinoma(PTC,group B) and 10 cases of normal thyroid tissues(group C,the control group)was detected by SP immunohistochemical method.The clinical data were analyzed.Results The expression level of Galectin-3 in group B was 83.03% (54/65),significantly higher than that in group A(19.35%,6/31) and group C(0%).The difference of group A and group B in terms of the expression level of Galectin-3 protein had statistical significance(x2 =36.360,P <0.05).The expression level of Cyclin D1 protein in group B was 72.30% (47/65),significantly higher than that in group A(12.90%,4/31)and group C(0%).The difference of group A and group B in terms of the expression level of Cyclin D1 protein had statistical significance(x2 =29.740,P < 0.05).The combination detection of the positive expression of Galectin-3 and Cyclin D1 in benign and malignant thyroid mass showed that the difference between group A and group B had statistical significance(P < 0.01).The expression of Galectin-3 and Cyclin D1 was positively correlated in group B(R =0.509,P <0.05).The positive expression rate of Cyclin D1 protein was 90% (18/20) and 64.44% (29/45)respectively in PTC patients with lymph node metastasis and without lymph node metastasis.The difference had statistical significance (P < 0.05).Conclusions The expression of Galectin-3 and Cyclin D1 is positively correlated in PTC and the expression of the 2 proteins in PTC is higher than that in nodular goiter and normal thyroid tissues,indicating that the 2 proteins can be used as valuable markers for patients with thyroid carcinoma.Combined detection of Cyclin D1 and Galectin-3 protein in thyroid tissues is useful for the diagnosis of thyroid cancer.